Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs October 26, 2026 2:30 PM EDT
Company Participants
Pablo Cagnoni – President and Global Head of R&D
Steven Stein – Executive VP, Head of Late-stage Development & Chief Medical Officer
Patrick Mayes – Vice President of Biotherapeutic Research
Alexis Smith – VP & Head of Investor Relations
Conference Call Participants
Elena Garralda
Manuel Hidalgo
Michael Schmidt – Guggenheim Securities, LLC, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Andrew Berens – Leerink Partners LLC, Research Division
Matthew Phipps – William Blair & Company L.L.C., Research Division
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Etzer Darout – Barclays Bank PLC, Research Division
Reni Benjamin – Citizens JMP Securities, LLC, Research Division
Tara Bancroft – TD Cowen, Research Division
Faisal Khurshid – Jefferies LLC, Research Division
Presentation
Pablo Cagnoni
President and Global Head of R&D
Good evening, everybody. Those of you here in Madrid, it’s been a wonderful ESMO for us at Incyte, and we’re really excited about telling you a lot of the progress we’re making in solid tumors. So thank you very much for joining us here today. We will be making forward-looking statements that you can see here.
We have a great set of speakers today. You can see them here on Steven Stein, Chief Medical Officer and Head of Late Development at Incyte; Dr. Elena Garralda, who’s Co-Director of the Vall d’Hebron Clinical Research Program and Group Leader for the Vall d’Hebron Early Clinical Drug Development Group as among many other titles; and Dr. Manuel Hidalgo, Professor of Medicine, Director of Gastrointestinal Cancer Center at the Perlmutter Cancer Center at NYU. So we’re really pleased and we’re very grateful that they agreed to join us here today.
We have a great agenda. I’m going to make a very — a couple of very quick comments to get